Advances in co-opting anti-depressant drugs in glioma therapy

Ayush Pant; Michael Lim

doi:10.1016/j.xcrm.2022.100837

Advances in co-opting anti-depressant drugs in glioma therapy

Cell Rep Med. 2022 Dec 20;3(12):100837. doi: 10.1016/j.xcrm.2022.100837.

Authors

Ayush Pant¹, Michael Lim²

Affiliations

¹ Department of Neurosurgery, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
² Department of Neurosurgery, School of Medicine, Stanford University, Stanford, CA, USA. Electronic address: mklim@stanford.edu.

Abstract

A study by Chryplewicz et al. demonstrated the efficacy of combining tricyclic antidepressant imipramine and anti-VEGF therapy in treating genetically engineered glioma models. Dual therapy synergistically improved vascular integrity, increased autophagy, and modulated the myeloid and lymphoid compartments in glioma.

Publication types

Comment

MeSH terms

Antidepressive Agents, Tricyclic / therapeutic use
Glioma* / drug therapy
Humans

Substances

Antidepressive Agents, Tricyclic

Grants and funding

T32 GM136577/GM/NIGMS NIH HHS/United States